Para IV Winners and Losers - April 2018
This month’s Para IV developments suggest that there is likely to be benefit to Cipla Ltd (CIPLA IN) on Xopenex HFA, Alvogen, Teva Pharmaceutical...
246 Views
Biosimilar Battlefield: An Update
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
518 Views
Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
594 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
838 Views
Health & Happiness: Not that Healthy After All and May Lead to Unhappy Shareholders?
Post the disclosure of the agreement that Swisse made with a JV that is owned by Procter & Gamble Co/The (PG US) and Teva Pharmaceutical Sp Adr...
498 Views